Apelin

PreclinicalSmall molecule

UUniversity of Edinburgh

Apelin is one of 114 small molecule programs targeting Pulmonary Hypertension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionActive, not recruiting

SystemicCompleted

InteractionCompleted

TIACompleted

Pulmonary HypertensionPreclinical

Active, not recruiting

SystemicPreclinical

Completed

InteractionPreclinical

Completed

TIAPreclinical

Completed

Competition

Competitive Landscape

62 competitors in Interaction

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

2 2

Robitussin

Pfizer

Phase 3

10 3

Epsom Salt

FFresenius Kabi USA, LLC

Approved

1 4

Rifadin

Sanofi

Phase 2

34 5

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

77 6

Rifampicin

Boehringer Ingelheim

Phase 3

22 7

Crestor

AstraZeneca

Phase 1

61 8

Lanoxin

AAdvanz Pharma

Phase 1

47 9

Tegretol

Oxycontin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Insulin Sensitivity2 trials

Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers

Completed·UUniversity Hospital, Toulouse·Phase 1·NCT02724566·9 enrolled

Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers

Completed·UUniversity Hospital, Toulouse·Phase 1·NCT02033473·16 enrolled

TIA1 trial

Investigating the Inotropic Potential of Apelin

Completed·UUniversity of Edinburgh·N/A·NCT01179061·24 enrolled

Cardiovascular1 trial

Cardiovascular Effects of Apelin In Healthy Volunteers

Completed·UUniversity of Edinburgh·Phase 1·NCT02259686·14 enrolled

Interaction1 trial

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

Completed·UUniversity of Edinburgh·N/A·NCT00901888·12 enrolled

Systemic1 trial

Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation

Completed·UUniversity of Edinburgh·N/A·NCT00901719·12 enrolled

2 more indications

Pulmonary Hypertension1 trial

Effects of Apelin on the Lung Circulation in Pulmonary Hypertension

Unknown status·GGolden Jubilee National Hospital·N/A·NCT01457170·63 enrolled

MODY1 trial

A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin

Unknown status·—·Phase 2·NCT03449251·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Apelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Edinburgh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Edinburgh

Apelin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Insulin Sensitivity2 trials

TIA1 trial

Cardiovascular1 trial

Interaction1 trial

Systemic1 trial

Pulmonary Hypertension1 trial

MODY1 trial

References

Drug Info

Quick Facts

Related News